News
LFCR
7.32
+3.54%
0.25
Lifecore Biomedical Selected by Nirsum Laboratories to Provide CDMO Services for NRS-033 Clinical Development
Barchart · 1d ago
Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025
Barchart · 1d ago
Lifecore selected by Nirsum Laboratories to provide CDMO services
TipRanks · 1d ago
Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
Barchart · 1d ago
Weekly Report: what happened at LFCR last week (1209-1213)?
Weekly Report · 4d ago
Weekly Report: what happened at LFCR last week (1202-1206)?
Weekly Report · 12/09 09:18
Lifecore management to meet virtually with Craig-Hallum
TipRanks · 12/02 21:20
Weekly Report: what happened at LFCR last week (1125-1129)?
Weekly Report · 12/02 09:18
Lifecore Biomedical: An Interesting CDMO Pure Play
Seeking Alpha · 12/01 15:40
Craig-Hallum Reaffirms Their Buy Rating on Lifecore Biomedical (LFCR)
TipRanks · 11/27 14:06
Lifecore Biomedical Secures Three-Year Extension of Credit Facility with BMO, Enhancing Financial Stability and Growth Opportunities
Barchart · 11/27 01:20
Lifecore Biomedical Strengthens Financial Position with Key Moves
TipRanks · 11/26 22:54
LIFECORE BIOMEDICAL INC - CREDIT FACILITY TERM EXTENDED TO NOVEMBER 2027
Reuters · 11/26 21:05
Press Release: Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO
Dow Jones · 11/26 21:05
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Soars 36% But It's A Story Of Risk Vs Reward
Simply Wall St · 11/26 12:21
Weekly Report: what happened at LFCR last week (1118-1122)?
Weekly Report · 11/25 09:17
Lifecore Biomedical Is Maintained at Buy by Craig-Hallum
Dow Jones · 11/22 17:20
Lifecore Biomedical Price Target Raised to $10.00/Share From $8.00 by Craig-Hallum
Dow Jones · 11/22 17:20
Craig-Hallum Maintains Buy on Lifecore Biomedical, Raises Price Target to $10
Benzinga · 11/22 17:09
Barrington Remains a Hold on Lifecore Biomedical (LFCR)
TipRanks · 11/22 14:15
More
Webull provides a variety of real-time LFCR stock news. You can receive the latest news about Lifecore Biomedical Inc through multiple platforms. This information may help you make smarter investment decisions.
About LFCR
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.